drugset / Trial / NCT05030129
ERG/5-HTP in Fragile X Syndrome (FXS)
Phase 2
Completed
15 enrolled
Elizabeth Berry-Kravis
FRAXA Research Foundation · collabPurposeful IKE · collab
RandomizedSequentialDouble-blindTreatment
Summary
The purpose of this study is to assess the safety, tolerability and efficacy of Ergoloid mesylates (EM) and 5-hydroxytryptophan (5-HTP) and the combination (EM + 5-HTP) compared to placebo in males aged 18-45 years old with Fragile X Syndrome.
Timeline
- Start
- 2021-10-07
- Primary completion
- 2023-01-19
- Completion
- 2023-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 5-Hydroxytryptophan | Other / unclassified | 100 mg | — |
| Subject | ERGOLOID | Unknown | 1 mg | — |